Clinical Trials | February 17, 2026
Roche’s Gazyva hits major milestone in rare kidney disease
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
The NIRSE-GAL study, conducted in Galicia, Spain, is the first real-world, population-based investigation of a universal RSV immunization program spanning two consecutive seasons
Duvakitug was well tolerated and safety was consistent with the induction study
Iberdomide has the potential to be the first approved CELMoD agent
If approved, Ameluz would become the first and only photodynamic therapy (PDT) photosensitizer for sBCC in the US
MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control
PreemieFort Enteral Solution's approval marks the first time a nutritional product derived from human milk has been recognized as a prescription medicine anywhere in the world
The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
Subscribe To Our Newsletter & Stay Updated
